Dublin, June 30, 2022 (GLOBE NEWSWIRE) -- The "Global Metastatic Cancer Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Cancer Type, Route of Administration, Drug Class, Product, and End User" report has been added to ResearchAndMarkets.com's offering.
The metastatic cancer drug market size is projected to reach US$ 68,349.54 million by 2028 from US$ 51,157.97 million in 2021. It is expected to grow at a CAGR of 4.2% from 2021 to 2028. The report highlights trends prevailing in the market and factors driving the metastatic cancer drug market growth.
The growth in the metastatic cancer drug market is attributed to the increasing prevalence of metastatic cancer across the world and rising government initiatives to support research and developments in cancer treatment. However, the high cost of oncology drugs restricts the market.
Metastatic cancer is defined as an advanced cancer stage that spreads to the other body parts, and the drugs used for the treatment of advanced-stage cancer are known as metastatic cancer drugs. These drugs are used through various therapies, such as chemotherapy, immunotherapy, and targeted therapy.
Governments of various countries are introducing missions and programs for quick and effective cancer treatment. In 2016, the US Government launched the Cancer Moonshot with three ambitious goals: To accelerate scientific cancer-related discovery, foster greater collaboration, and improve data sharing. The cancer patient community and medical researchers responded with tremendous energy and ingenuity to this campaign.
On February 2, 2022, the Cancer Moonshot project was relaunched by highlighting new goals of reducing the death rate of cancer by at least 50% over the next 25 years, improving the experience of people and their families living with and surviving cancer, and putting an end to cancer through these efforts. By focusing on the areas of cancer research and encouraging new investments that are most likely to benefit patients, the Cancer Moonshot has brought together a large community of investigators and clinicians dedicated to expediting research to improve the lives of patients.
In 2020, 2.7 million people in the European Union were diagnosed with the disease, and another 1.3 million people lost their lives to it. The EU has been working to tackle cancer for decades and its actions, for example tobacco control and protection from hazardous substances, have saved and prolonged lives. Europe's Beating Cancer Plan is the EU's response to the need for cancer treatment. It reflects a political commitment to leave no stone unturned to take action against cancer.
Mobilizing the collective power of the EU to drive change for the benefit of the citizens, the Cancer Plan contains concrete, ambitious actions that will support, coordinate and complement Member States' efforts to reduce the suffering caused by cancer. Over the coming years, it will focus on research and innovation, tap into the process of digitalization and offer new technologies, and mobilize financial instruments to support the Member States.
The European Medicines Agency introduced and authorized a drug named Trodelvy that exhibits greater benefits than its risks. In January 2021, AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s Enhertu (trastuzumab deruxtecan) were granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens. In Europe, over 531,000 breast cancer cases in women are diagnosed per year, with approximately 1 in 5 patients being HER2-positive. The impact of the disease is significant, with breast cancer responsible for more than 141,000 deaths annually in Europe.
In January 2022, AbbVie announced that the US FDA granted Breakthrough Therapy Designation (BTD) to investigate the telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.
Key Topics Covered:
1. Introduction
2. Metastatic Cancer Drugs Market - Key Takeaways
3. Research Methodology
4. Global Metastatic Cancer Drugs Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 South & Central America - PEST Analysis
4.2.5 Middle East & Africa - PEST Analysis
4.3 Expert Opinion
5. Metastatic Cancer Drugs Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 High Prevalence of Metastatic Cancer
5.1.2 Government Initiatives to Support Developments in Cancer Treatment
5.2 Market Restraints
5.2.1 High Cost of Oncology Drugs
5.3 Market Opportunities
5.3.1 Investments in Artificial Intelligence for Oncology Drug Development
5.4 Future Trends
5.4.1 Increase in Launch of Metastatic Cancer Drugs
5.5 Impact analysis
6. Metastatic Cancer Drugs Market - Global Analysis
6.1 Global Metastatic Cancer Drugs Market Revenue Forecast and Analysis
6.1.1 Global Metastatic Cancer Drugs Market, By Geography - Forecast and Analysis
6.1.2 Global Metastatic Cancer Drugs Market - Market Potential Analysis, By Region
6.2 Company Analysis
6.2.1 Market Positioning of Key Players
6.2.2 Comparative Company Analysis
6.2.3 Growth Strategy Analysis
6.2.4 Performance of Key Players
6.2.4.1 Celgene Corporation
6.2.4.2 Novartis AG
7. Metastatic Cancer Drug Market Analysis - By Cancer Type
7.1 Overview
7.2 Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)
7.3 Breast Cancer
7.3.1 Overview
7.3.2 Breast Cancer: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Lung Cancer
7.4.1 Overview
7.4.2 Lung Cancer: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Liver Cancer
7.5.1 Overview
7.5.2 Liver Cancer: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Hematological Cancer
7.6.1 Overview
7.6.2 Hematological Cancer: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
7.7 Brain Cancer
7.7.1 Overview
7.7.2 Brain Cancer: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
7.8 Prostate Cancer
7.8.1 Overview
7.8.2 Prostate Cancer: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
7.9 Pancreatic Cancer
7.9.1 Overview
7.9.2 Pancreatic Cancer: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
8. Metastatic Cancer Drug Market - By Route of Administration
8.1 Overview
8.2 Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)
8.3 Intravenous
8.3.1 Overview
8.3.2 Intravenous: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Intramuscular
8.4.1 Overview
8.4.2 Intramuscular: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
8.5 Oral
8.5.1 Overview
8.5.2 Oral: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
9. Metastatic Cancer Drug Market - By Drug Class
9.1 Overview
9.2 Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)
9.3 HER2 Inhibitors
9.3.1 Overview
9.3.2 HER2 Inhibitors: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
9.4 Immune Checkpoints Inhibitors
9.4.1 Overview
9.4.2 Immune Checkpoints Inhibitors: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
9.5 PARP Inhibitors
9.5.1 Overview
9.5.2 PARP Inhibitors: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
9.6 Kinase Inhibitors
9.6.1 Overview
9.6.2 Kinase Inhibitors: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
10. Metastatic Cancer Drug Market - By Product
10.1 Overview
10.2 Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)
10.3 Branded
10.3.1 Overview
10.3.2 Branded: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
10.4 Generics and Biosimilars
10.4.1 Overview
10.4.2 Generics and Biosimilars: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
11. Metastatic Cancer Drug Market - By End User
11.1 Overview
11.2 Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)
11.3 Hospital
11.3.1 Overview
11.3.2 Hospitals: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
11.4 Specialty Clinic
11.4.1 Overview
11.4.2 Specialty Clinics: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
11.5 Others
11.5.1 Overview
11.5.2 Others: Metastatic Cancer Drug Market - Revenue and Forecast to 2028 (US$ Million)
12. Metastatic Cancer Drugs Market - Regional Analysis
13. Impact of COVID-19 Pandemic on Global Metastatic Cancer Drugs Market
13.1 North America: Impact Assessment of COVID-19 Pandemic
13.2 Europe: Impact Assessment of COVID-19 Pandemic
13.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
13.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
13.5 South and Central America: Impact Assessment of COVID-19 Pandemic
14. Metastatic Cancer Drug Market - Industry Landscape
14.1 Overview
14.2 Growth Strategies in the Metastatic Cancer Drug Market, 2021-2028
14.3 Inorganic Developments
14.3.1 Overview
14.4 Organic Growth Strategies
14.4.1 Overview
15. Company Profiles
15.1 AbbVie Inc.
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Amgen Inc.
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Bristol-Myers Squibb Company
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 F. HOFFMANN-LA ROCHE LTD.
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 Novartis AG
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 Astrazeneca
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 Eli Lilly and Company.
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 MERCK KGaA
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Pfizer Inc. (Arena Pharmaceutical GmbH)
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Johnson and Johnson Services, Inc.
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
16. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/h4sw5y
Attachment
